Federal Register / Vol. 85, No. 248 / Monday, December 28, 2020 / Notices 84355 

intervals, setting forth the committee 

meeting dates and Respondent’s 

compliance with appropriate research 

standards and confirming the integrity 

of Respondent’s research. 

ii. The committee will conduct an 

advance review of any PHS grant 

applications (including supplements, 

resubmissions, etc.), manuscripts 

reporting PHS-funded research 

submitted for publication, and abstracts. 

The review will include a discussion 

with Respondent of the primary data 

represented in those documents and 

will include a certification to ORI that 

the data presented in the proposed 

application/publication are supported 

by the research record. 

(3) Respondent agreed that for a 

period of three (3) years beginning on 

December 8, 2020, any institution 

employing her shall submit, in 

conjunction with each application of 

PHS funds, or report, manuscript, or 

abstract involving PHS-supported 

research in which Respondent is 

involved, a certification to ORI that the 

data provided by Respondent are based 

on actual experiments or are otherwise 

legitimately derived and that the data, 

procedures, and methodology are 

accurately reported in the application, 

report, manuscript, or abstract. 

(4) If no supervisory plan is provided 

to ORI, Respondent agreed to provide 

certification to ORI at the conclusion of 

the supervision period that she has not 

engaged in, applied for, or had her name 

included on any application, proposal, 

or other request for PHS funds without 

prior notification to ORI. 

(5) Respondent agreed to exclude 

herself voluntarily from serving in any 

advisory capacity to PHS including, but 

not limited to, service on any PHS 

advisory committee, board, and/or peer 

review committee, or as a consultant for 

a period of three (3) years, beginning on 

December 8, 2020. 

Dated: December 21, 2020. 

Elisabeth A. Handley, 

Director, Office of Research Integrity, Office 

of the Assistant Secretary for Health. 

[FR Doc. 2020–28566 Filed 12–23–20; 8:45 am] 

BILLING CODE 4150–31–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Biomedical Devices for Ventricular Repair. 

Date: January 22, 2021. 

Time: 10:00 a.m. to 12:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6705 

Rockledge Drive, Bethesda, MD 20817 

(Virtual Meeting). 

Contact Person: Stephanie J Webb, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, National Institutes of Health, 

6705 Rockledge Drive, Room 208–V, 

Bethesda, MD 20892, (301) 827–7992, 

stephanie.webb@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: December 18, 2020. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2020–28527 Filed 12–23–20; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of 

meetings of the National Diabetes and 

Digestive and Kidney Diseases Advisory 

Council. 

The meeting will be open to the 

public as indicated below, with a short 

public comment period at the end. The 

open session will be videocast and can 

be accessed from the NIH Videocasting 

and Podcasting website (http://

videocast.nih.gov). 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Diabetes and 

Digestive and Kidney Diseases Advisory 

Council. 

Date: September 1–2, 2021. 

Open: September 01, 2021, 10:00 a.m. to 

1:15 p.m. 

Agenda: To present the Director’s Report 

and other scientific presentations. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Closed: September 02, 2021, 1:25 p.m. to 

1:45 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Karl F. Malik, Ph.D., 

Director, Division of Extramural Activities, 

National Institutes of Diabetes and Digestive 

and Kidney Diseases, 6707 Democracy 

Boulevard, Room 7329, MSC 5452, Bethesda, 

MD 20892, (301) 594–4757, malikk@

niddk.nih.gov. 

Name of Committee: National Diabetes and 

Digestive and Kidney Diseases Advisory 

Council; Digestive Diseases and Nutrition 

Subcommittee. 

Date: September 1–2, 2021. 

Open: September 02, 2021, 10:00 a.m. to 

11:30 a.m. 

Agenda: To review the Division’s scientific 

and planning activities. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Closed: September 02, 2021, 11:45 a.m. to 

1:15 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Karl F. Malik, Ph.D., 

Director, Division of Extramural Activities, 

National Institutes of Diabetes and Digestive 

and Kidney Diseases, 6707 Democracy 

Boulevard, Room 7329, MSC 5452, Bethesda, 

MD 20892, (301) 594–4757, malikk@

niddk.nih.gov. 

Name of Committee: National Diabetes and 

Digestive and Kidney Diseases Advisory 

Council; Diabetes, Endocrinology and 

Metabolic Diseases Subcommittee. 

Date: September 1–2, 2021. 

Open: September 02, 2021, 10:00 a.m. to 

11:30 a.m. 

Agenda: To review the Division’s scientific 

and planning activities. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 


tkelley on DSKBCP9HB2PROD with NOTICES
84356 Federal Register / Vol. 85, No. 248 / Monday, December 28, 2020 / Notices 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Closed: September 02, 2021, 11:45 a.m. to 

1:15 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Karl F. Malik, Ph.D., 

Director, Division of Extramural Activities, 

National Institutes of Diabetes and Digestive 

and Kidney Diseases, 6707 Democracy 

Boulevard, Room 7329, MSC 5452, Bethesda, 

MD 20892, (301) 594–4757, malikk@

niddk.nih.gov. 

Name of Committee: National Diabetes and 

Digestive and Kidney Diseases Advisory 

Council Kidney, Urologic and Hematologic 

Diseases Subcommittee. 

Date: September 1–2, 2021. 

Open: September 02, 2021, 10:00 a.m. to 

11:30 a.m. 

Agenda: To review the Division’s scientific 

and planning activities. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Closed: September 02, 2021, 11:45 a.m. to 

1:15 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Karl F. Malik, Ph.D., 

Director, Division of Extramural Activities, 

National Institutes of Diabetes and Digestive 

and Kidney Diseases, 6707 Democracy 

Boulevard, Room 7329, MSC 5452, Bethesda, 

MD 20892, (301) 594–4757, malikk@

niddk.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: 

www.niddk.nih.gov/fund/divisions/DEA/ 

Council/coundesc.htm., where an agenda and 

any additional information for the meeting 

will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: December 18, 2020. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2020–28523 Filed 12–23–20; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Minority Health 

and Health Disparities; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be held as a virtual 

meeting and is open to the public as 

indicated below. Individuals who plan 

to view the virtual meeting and need 

special assistance or other reasonable 

accommodations to view the meeting, 

should notify the Contact Person listed 

below in advance of the meeting. The 

open session will be videocast and can 

be accessed from the NIH Videocasting 

and Podcasting website (http://

videocast.nih.gov/). 

A portion of the meeting will be 

closed to the public in accordance with 

the provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Council on Minority Health and Health 

Disparities. 

Date: February 1, 2021. 

Closed: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Name of Committee: National Advisory 

Council on Minority Health and Health 

Disparities. 

Date: February 2, 2021. 

Open: 11:00 a.m. to 4:00 p.m. 

Agenda: Opening Remarks, Administrative 

Matters, Director’s Report, Presentations, and 

Other Business of the Council. 

Place: National Institutes of Health, 6707 

Democracy Boulevard, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Thomas M. Vollberg, Sr., 

Ph.D., National Institute on Minority Health 

and Health Disparities, National Institutes of 

Health, 6707 Democracy Boulevard, Suite 

800, Bethesda, Maryland 20892–5465, 301– 

402–1366, Thomas.Vollberg@nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: NIMHD: 

https://www.nimhd.nih.gov/about/advisorycouncil/, where an agenda and any additional 

information for the meeting will be posted 

when available. 

Dated: December 18, 2020. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2020–28528 Filed 12–23–20; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Development and 

Commercialization of Chimeric Antigen 

Receptor (CAR) Therapies for the 

Treatment of FMS-Like Tyrosine 

Kinase 3 (FLT3) Expressing 

Malignancies Using Natural Killer Cells 

(NK Cells) Transduced With Retroviral 

or Lentiviral Vectors 

AGENCY: National Institutes of Health, 

HHS 

ACTION: Notice 

SUMMARY: The National Cancer Institute, 

an institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

Patents and Patent Applications listed 

in the Supplementary Information 

section of this Notice to Senti Bio 

(‘‘Senti’’), located in South San 

Francisco, CA. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Cancer 

Institute’s Technology Transfer Center 

on or before January 12, 2021 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent applications, inquiries, and 

comments relating to the contemplated 

Exclusive Patent License should be 

directed to: at Email: jim.knabb@

nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

E–133–2016–0: FLT3-Specific Chimeric 

Antigen Receptors and Methods Using 

Same 

1. US Provisional Patent Application 

62/342,394, filed May 27, 2016 (E– 

133–2016–0–US–01) 

2. International Patent Application PCT/ 

US2017/034,691, filed May 26, 

2017 (E–133–2016–0–PCT–02) 

3. EP Patent Application 

No.:17729627.4, filed December 11, 

2018 (E–133–2016/0–EP–03) 


tkelley on DSKBCP9HB2PROD with NOTICES